Immunotec and Nova Southeastern University (NSU) Collaborate on New Autism Study using Immunocal® PR Newswire MONTREAL, July 26, 2011 MONTREAL, July 26, 2011 /PRNewswire/ - Immunotec Inc. (TSXV:...
Important New Research using Immunocal® Shows Promise in Lou Gehrig's Disease PR Newswire MONTREAL, June 14, 2011 MONTREAL, June 14, 2011 /PRNewswire/ - Immunotec Inc. (TSXV: IMM...
NEW YORK, May 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (OTC:IMMP) announced today that the Company expects to begin trading its common stock on the Pink OTC Markets quotation...
NEW YORK, April 21 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that the Company is reorganizing its R&D operations. This restructuring will direct...
NEW YORK, April 3 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Amex: IMM) announced today that it has made an investment in Gold Avenue Ltd., a privately-held Hong Kong company...
NEW YORK, April 2 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE AMEX: IMM) today announced that on March 27, 2009, the Company received notice from the NYSE Amex LLC (the...
NEW YORK, Feb. 27 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced that the Company has signed a Memorandum of Understanding (MOU) confirming...
NEW YORK, Feb. 13 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM) announced today that the Company will postpone the quarterly update conference call scheduled...
NEW YORK, Jan. 20 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced that the Company has appointed Virchow, Krause & Company, LLP as its...
NEW YORK, Jan. 16 /PRNewswire-FirstCall/ -- Immtech Pharmaceuticals, Inc. (NYSE Alternext US: IMM.BC) today announced that the Company has entered into an agreement to sell Immtech Life Science...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관